Dr. Minghua Zheng, MD, PhD

Position:

· Professor, MAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University

Institution:

· The First Affiliated Hospital of Wenzhou Medical University

Academic Degrees:

· 2013.9 - 2016.7: Ph.D. in Liver Diseases, Wenzhou Medical University, Wenzhou, China

· 2005.9 - 2008.7: M.D. in Liver Diseases, Wenzhou Medical University, Wenzhou, China

· 1998.9 - 2003.7: M.D. in Medical Science, Wenzhou Medical University, Wenzhou, China

Academic and Professional Employment:

· 2020.12 - Present: Professor, MAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University

Articles Published in Peer-Reviewed Journals:

1. Au K, Zheng MH, Lee WJ, et al. Resmetirom and Metabolic Dysfunction-Associated Steatohepatitis: Perspectives on Multidisciplinary Management from Global Healthcare Professionals. Curr Obes Rep. 2024.

2. Feng G, Han Y, Yang W, et al. Recompensation in MASLD-related cirrhosis via metabolic bariatric surgery. Trends Endocrinol Metab. 2024.

3. Feng G, He N, Gao J, et al. Causal relationship between key genes and metabolic dysfunction-associated fatty liver disease risk mediated by immune cells: A Mendelian randomization and mediation analysis. Diabetes Obes Metab. 2024.

4. Feng G, Mózes FE, Ji D, et al. acFibroMASH index for the diagnosis of fibrotic MASH and prediction of liver-related events: An international multicenter study. Clin Gastroenterol Hepatol. 2024.

5. Lu K, He L, Guo Z, et al. PDCD4 deficiency in hepatocytes exacerbates nonalcoholic steatohepatitis through enhanced MHC class II transactivator expression. Metabolism. 2024: 156036.

6. Miao L, Ye SM, Zheng MH. "Fatty" or "steatotic": position statement from a linguistic perspective by the Chinese-speaking community. J Hepatol. 2024.

7. Song L, Hou Y, Xu D, et al. Hepatic FXR-FGF4 is required for bile acid homeostasis via an FGFR4-LRH-1 signal node under cholestatic stress. Cell Metab. 2024.

8. Tong X, Sun Y, Wang Q, et al. Delicate and thin fibrous septa indicate a regression tendency in metabolic dysfunction-associated steatohepatitis patients with advanced fibrosis. Hepatol Int. 2024.

9. Yang Y, Lu J, Liu Y, et al. Improvement of MASLD and MASH by suppression of hepatic N-Acetyltransferase 10. Mol Metab. 2024: 102030.

10. Yuan HY, Liu WY, Feng G, et al. Associations between cuprotosis-related genes and the spectrum of metabolic dysfunction-associated fatty liver disease: An exploratory study. Diabetes Obes Metab. 2024.

11. Zhang S, Yan Y, Zeng XF, et al. Associations of the EAT-Lancet reference diet with metabolic dysfunction-associated steatotic liver disease and its severity: a multi-cohort study. Hepatology. 2024.

12. Zhou B, Luo Y, Bi H, et al. Amelioration of nonalcoholic fatty liver disease by inhibiting the deubiquitylating enzyme RPN11. Cell Metab. 2024.

13. Zhou YH, Kehar M, Ng NBH, Zheng MH. Letter: Resmetirom for treatment of MASH with children and adolescents. Aliment Pharmacol Ther. 2024.

14. Sun DQ, Zheng KI, Xu G, et al. PNPLA3 rs738409 is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels. Liver Int. 2020; 40(1): 107-19.

15. Dai H, Zhu C, Huai Q, et al. Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models. J Hepatol. 2024; 80(6): 913-27.

16. Lazarus JV, Mark HE, Anstee QM, et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022; 19(1): 60-78.

17. Fan R, Li G, Yu N, et al. aMAP Score and Its Combination With Liver Stiffness Measurement Accurately Assess Liver Fibrosis in Chronic Hepatitis B Patients. Clin Gastroenterol Hepatol. 2023; 21(12): 3070-9.e13.

18. Rios RS, Zheng KI, Zheng MH. Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma. Chin Med J. 2021; 134(24): 2911-21.

19. Sun DQ, Wu SJ, Liu WY, et al. Serum uric acid: a new therapeutic target for nonalcoholic fatty liver disease. Expert Opin Ther Targets. 2016; 20(3): 375-87.

20. Lazarus JV, Mark HE, Allen AM, et al. A global research priority agenda to advance public health responses to fatty liver disease. J Hepatol. 2023; 79(3): 618-34.

Contact Information:

· Phone: +86-13587873910, +86-577-55579127 (work)

· E-mail: jiangleistone79@163.com; lei.jiang@wmu.edu.cn